Shopping Cart
- Remove All
Your shopping cart is currently empty
SSR128129E free acid
😃Good
Catalog No. T13003Cas No. 848463-13-8
Alias SSR free acid
SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1.
SSR128129E free acid
😃Good
Catalog No. T13003Alias SSR free acidCas No. 848463-13-8
SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 1-2 weeks | |
| 50 mg | $1,980 | 1-2 weeks | |
| 100 mg | $2,500 | 1-2 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "SSR128129E free acid"
Ferulic Acid
Cited
Fumalic Acid, Coniferic acid
T22151135-24-6
Ferulic Acid (Coniferic acid) is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.
- $30
Size
QTY
CitedPazopanib
GW786034
T0097L444731-52-6
Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms (IC50=10/30/47/84/74/140/146 nM). Pazopanib has antitumor activity.
- $42
Size
QTY
Amlexanox
Cited
CHX3673, Amoxanox, AA673
T163968302-57-8
Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers.
- $32
Size
QTY
CitedFormononetin Cited
Formononetol, Flavosil, Biochanin B
T0724485-72-3
Formononetin (Flavosil) is an O-methylated isoflavone and a phytoestrogen from the root of Astragalus membranaceus.
- $45
Size
QTY
CitedNintedanib Cited
Intedanib, BIBF 1120
T1777656247-17-5
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
- $38
Size
QTY
CitedLenvatinib mesylate Cited
E7080 (mesylate)
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
- $34
Size
QTY
CitedErdafitinib Cited
JNJ-42756493
T37261346242-81-6
Erdafitinib (JNJ-42756493), a quinoxaline derivative, targets FGFR1/2/3/4.
- $39
Size
QTY
CitedLenvatinib Cited
E7080
T0520417716-92-8
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
- $40
Size
QTY
CitedNintedanib esylate
Nintedanib Ethanesulfonate Salt, BIBF 1120 (esylate)
T5001656247-18-6
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β.
- $36
Size
QTY
Pemigatinib Cited
INCB054828
T124011513857-77-6
Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR, with IC50 values of 0.4 nM for FGFR1, 0.5 nM for FGFR2, 1.2 nM for FGFR3, and 30 nM for FGFR4.
- $41
Size
QTY
CitedMasitinib
AB1010
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1. |
| Targets&IC50 | FGFR1:1.9 μM |
| In vitro | FGF2-induced EC proliferation(IC50 : 31±1.6 nM) inhibited by SSR128129E, migration with an IC50 of 15.2±4.5 nM, and lamellipodia formation in a dose dependent manner. SSR128129E inhibits responses mediated by FGFR1-4. SSR128129E blocks EC migration in response to FGF1, a ligand of FGFR1 and FGFR4, and capillary tube formation in response to FGF19, a ligand of FGFR4. Proliferation and migration of the murine pancreatic Panc02 tumor cell line in response to FGF7 are also blocked by SSR128129E, showing that SSR128129E inhibits FGFR subtypes of other species as well. |
| In vivo | Oral delivery of SSR128129E (30 mg/kg/day, from day 3) inhibits the growth of orthotopic Panc02 tumors by 44% and delays the growth of Lewis lung carcinoma. Administering SSR128129E orally (30 mg/kg/day, from day 5) reduces tumor size and weight by 53% and 40%, respectively. SSR128129E also inhibits the growth of subcutaneous CT26 colon tumors by 34% and the multidrug-resistant MCF7/ADR breast cancer xenograft model by 40%. Additionally, the compound reduces tumor invasiveness and metastasis of Panc02 tumor cells to peritoneal lymph nodes. |
| Alias | SSR free acid |
| Molecular Weight | 324.33 |
| Formula | C18H16N2O4 |
| Cas No. | 848463-13-8 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy SSR128129E free acid | purchase SSR128129E free acid | SSR128129E free acid cost | order SSR128129E free acid | SSR128129E free acid chemical structure | SSR128129E free acid in vivo | SSR128129E free acid in vitro | SSR128129E free acid formula | SSR128129E free acid molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.